Kera Capital Partners Inc. Buys Shares of 4,684 Astrazeneca Plc $AZN

Kera Capital Partners Inc. bought a new position in Astrazeneca Plc (NYSE:AZN) during the 4th quarter, Holdings Channel.com reports. The fund bought 4,684 shares of the company’s stock, valued at approximately $822,000.

A number of other large investors have also made changes to their positions in the company. MV Capital Management Inc. purchased a new stake in shares of Astrazeneca during the 4th quarter valued at about $26,000. Hamilton Wealth LLC boosted its holdings in shares of Astrazeneca by 16.5% in the fourth quarter. Hamilton Wealth LLC now owns 6,478 shares of the company’s stock worth $1,137,000 after buying an additional 918 shares during the last quarter. Compound Planning Inc. boosted its holdings in shares of Astrazeneca by 29.3% in the fourth quarter. Compound Planning Inc. now owns 42,583 shares of the company’s stock worth $7,473,000 after buying an additional 9,655 shares during the last quarter. Invesco Ltd. grew its position in Astrazeneca by 5.0% during the fourth quarter. Invesco Ltd. now owns 4,406,716 shares of the company’s stock valued at $773,379,000 after buying an additional 210,419 shares during the period. Finally, Corient Private Wealth LLC increased its holdings in Astrazeneca by 55.9% during the fourth quarter. Corient Private Wealth LLC now owns 331,081 shares of the company’s stock valued at $58,105,000 after buying an additional 118,703 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Barclays reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Wall Street Zen upgraded Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Finally, TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Astrazeneca currently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Price Performance

Shares of NYSE:AZN opened at $174.87 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The company has a market capitalization of $271.20 billion, a P/E ratio of 26.26, a P/E/G ratio of 1.55 and a beta of 0.25. The firm’s 50 day simple moving average is $187.22 and its two-hundred day simple moving average is $186.24.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Research analysts expect that Astrazeneca Plc will post 9.39 EPS for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.